# A+C in Metastatic Lung Adenocarcinoma Cancer

> **NCT02946359** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Lung Adenocarcinoma Metastatic

## Interventions

- **DRUG:** Crizotinib, bevacizumab

## Key facts

- **NCT ID:** NCT02946359
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2017-10
- **Final completion:** 2018-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02946359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02946359, "A+C in Metastatic Lung Adenocarcinoma Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02946359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*